幕上脑出血内镜清除术后高术后血肿周围水肿轨迹
这项两中心回顾性队列纳入136例幕上脑出血内镜清除术后存活超72小时且具备完整CT及90天mRS的患者。高术后血肿周围水肿轨迹定义为T3血肿周围水肿≥36.6 mL,或T1-T2-T3持续增加且T3-T1变化≥7.7 mL,共51例(37.5%)。脑室内出血严重程度、残余血肿体积和72小时内发热持续时间与该轨迹相关。将该轨迹加入模型后AUC从0.846升至0.905,轨迹与不良预后(mRS 3-6)的aOR为25.21(95% CI 6.13-103.60)。
要点
- 高术后血肿周围水肿轨迹定义为T3血肿周围水肿≥36.6 mL,或T1-T2-T3持续增加且T3-T1变化≥7.7 mL,两者均为队列衍生的上四分位数阈值。
- 高术后血肿周围水肿轨迹患者90天不良预后(mRS 3-6)的调整后比值比达25.21(95% CI 6.13-103.60)。
- 脑室内出血严重程度每增加一个类别,高轨迹aOR为2.11(95% CI 1.09-4.09);残余血肿体积每增加1 mL,aOR为1.75(95% CI 1.35-2.27)。
- 术后72小时内发热持续时间每增加1小时,高轨迹aOR为1.20(95% CI 1.08-1.34)。
- 将高轨迹加入预后模型后,表观AUC从0.846增加到0.905。
适用人群与场景
- 幕上脑出血接受内镜清除术后存活超过72小时的患者。
- 具备完整连续CT(T1为0-24小时,T2为48-72小时,T3为第5-7天)和90天mRS评估的患者。
- 两中心回顾性队列共136例患者。
诊断标准与关键阈值
- 高术后血肿周围水肿轨迹:T3血肿周围水肿≥36.6 mL,或T1-T2-T3持续增加且T3-T1变化≥7.7 mL;两个阈值均为队列衍生的上四分位数。
- 不良预后定义为90天mRS评分3-6分。
- CT评估时间窗:T1为0-24小时,T2为48-72小时,T3为第5-7天。
处置流程与药物剂量
- 原文为观察性研究,未提供治疗性处置流程或药物剂量推荐。
红旗征与不能漏的情况
- 术后早期(72小时内)发热持续时间延长与高术后血肿周围水肿轨迹相关(aOR 1.20每小时,95% CI 1.08-1.34),需关注发热管理。
- 脑室内出血严重程度增加与高轨迹相关(aOR 2.11每类别,95% CI 1.09-4.09),提示脑室内出血量大的患者需警惕。
- 残余血肿体积每增加1 mL与高轨迹相关(aOR 1.75,95% CI 1.35-2.27),术后残余血肿量应作为重点评估指标。
研究设计与关键结果
- 研究类型:两中心回顾性队列,136例幕上脑出血内镜清除术后存活超72小时且具备完整CT及90天mRS的患者。
- 高术后血肿周围水肿轨迹发生率为37.5%(51/136例)。
- 高轨迹与90天不良预后(mRS 3-6)的aOR为25.21(95% CI 6.13-103.60)。
- 加入轨迹后模型表观AUC从0.846增加至0.905。
- 脑室内出血严重程度(aOR 2.11每类别,95% CI 1.09-4.09)、残余血肿体积(aOR 1.75每mL,95% CI 1.35-2.27)、72小时内发热持续时间(aOR 1.20每小时,95% CI 1.08-1.34)均与高轨迹相关。
- 131对配对观察中,90天mRS 0-2为54.2%(71/131),12个月为58.0%(76/131),两侧精确McNemar检验P=0.125。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:两中心、回顾性设计、样本量小(136例)、研究对象为早期术后幸存者、轨迹定义为队列衍生上四分位数阈值、仅报告表观AUC未做外部验证、未报告原文给定的正式证据等级或推荐强度。
对床旁实践的改变
- 该研究提示在内镜清除幕上脑出血术后早期幸存者中,T3血肿周围水肿≥36.6 mL或T1-T2-T3持续增加且T3-T1变化≥7.7 mL可作为识别预后不良高危患者的候选影像标志物,但需外部验证后才能用于床旁决策。
- 术后72小时内发热持续时间、脑室内出血严重程度、残余血肿体积是高轨迹的可改变或可评估相关因素,但不能据此确定干预阈值。
- 不适用于未接受内镜清除术、其他部位脑出血或术后72小时内死亡的患者。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND OBJECTIVE: The clinical relevance of perihematomal edema (PHE) after endoscopic evacuation of supratentorial intracerebral hemorrhage (ICH) is uncertain. We examined a longitudinal postoperative PHE phenotype and its association with 90-day functional outcome.
METHODS: This two-center retrospective cohort included 136 patients who survived beyond 72 h after endoscopic evacuation of supratentorial ICH and had complete serial computed tomography (CT) and 90-day modified Rankin Scale (mRS) assessment. CT windows were 0-24 h (T1), 48-72 h (T2), and day 5-7 (T3). Before outcome-model fitting, high postoperative PHE trajectory was defined as T3 PHE ≥ 36.6 mL or continuous increase across T1-T2-T3 with a T3-T1 change ≥ 7.7 mL; both thresholds were cohort-derived upper quartiles. Center-adjusted logistic regression examined associated factors and poor 90-day outcome (mRS score 3-6).
RESULTS: High postoperative PHE trajectory occurred in 51 patients (37.5%). Intraventricular hemorrhage (IVH) severity (adjusted odds ratio [aOR] 2.11 per category, 95% confidence interval [CI] 1.09-4.09), residual hematoma volume (aOR 1.75 per mL, 95% CI 1.35-2.27), and fever duration within 72 h (aOR 1.20 per h, 95% CI 1.08-1.34) were associated with this trajectory. Adding trajectory to the outcome model increased apparent area under the receiver operating characteristic curve (AUC) from 0.846 to 0.905; trajectory was associated with poor outcome (aOR 25.21, 95% CI 6.13-103.60). Among 131 paired observations, mRS score 0-2 occurred in 71/131 (54.2%) at 90 days and 76/131 (58.0%) at 12 months (two-sided exact McNemar P = 0.125).
CONCLUSIONS: In this selected cohort of early postoperative survivors, IVH severity, residual hematoma volume, and fever duration were associated with high postoperative PHE trajectory, which was associated with poor 90-day functional outcome. This cohort-derived imaging phenotype warrants external validation as a candidate prognostic marker after endoscopic evacuation.
参考来源
- Liu, Li, Su, et al. High Postoperative Perihematomal Edema Trajectory after Endoscopic Evacuation for Supratentorial Intracerebral Hemorrhage. Neurocrit Care. 2026. PMID: 42946955. doi:10.1007/s12028-026-02707-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。